Gene

All sections on this page are required unless otherwise specified. Important fields are highlighted. Incomplete information could result in a delay of testing.

PATIENT INFORMATION					
First Name	Last Name				
Sex Assigned at Birth: () Male () Female	Date of Birth (mm/dd/	уу)			
Patient Karyotype (if known):					
Gender Identification (optional):					
Email					
Address					
City	State	Zip Code			
Primary Phone	Is this patient decease Deceased Date:	d? O Yes O No			

SAMPLE INFORMATION				
Date Sample Collected (mm/dd/yy)	Medical Record #			
O Blood O Buccal Swab O Other (specify source):				
Treatment-related RUSH (optional) Reason: O Transplantation O Pregnancy O Surgery O Other:				
Patient has had a blood transfusion Oyes O No Date of Last Transfusion:				
Patient has had an allogeneic bone marrow transplant () Yes () No Fibroblasts are required for patients who had an allogeneic bone marrow transplant. See www.genedx.com/specimen-requirements for details.				
Patient has a personal history of a hematologic malignancy or disease O Yes (specify diagnosis) ONo				

If yes, please call the lab to discuss with a genetic counselor the most appropriate sample type.

PATIENT CONSENT

By signing this form, I acknowledge as the patient or relative being tested that I have read or have had read to me the GeneDx Informed Consent document at the end of this test requisition form, and understand the information regarding molecular genetics testing. I have had the opportunity to ask questions about the testing, the procedure, the risks, and the alternatives. By signing this form, I authorize GeneDx to perform genetic testing as ordered. I understand that, for tests that evaluate data from multiple family members concurrently, test results from these family members may be included in a single comprehensive report that will be made available to all tested individuals and their healthcare providers.

- By checking this box, I confirm that I am a New York State resident, and I give permission for GeneDx to retain any remaining sample longer than 60 days after the completion of testing, and to be used as a de-identified sample for test development and improvement, internal validation, quality assurance, and training purposes. Otherwise, New York law requires GeneDx to destroy my sample within 60 days, and it cannot be used for test development studies.
- Check this box if you wish to opt out of being contacted for research studies

Check this box if you do not wish to receive ACMG secondary findings (Full Exome Sequencing and Genome Sequencing Tests ONLY; not for Xpanded® or Slice tests).

Signature of Patient/Legal Guar	dian (required)	Date
Signature of Relative A/Legal Gu	Date	
Signature of Relative B/Legal Gu	lardian	Date
FOR COMMERCIAL INSURANCE O By entering my preferred contact me with an estimate of the patien	NLY: information below, I give my p t's financial responsibility for t	ermission to GeneDx to contact esting. Data rates may apply.
Email (required)*	Mobile Numbe	ər

ACCOUNT INFORMATION					
GeneDx Account Number	Account Name				
Phone	Fax				
Address					
City	State	Zip Code			
Ordering Provider Name		Role/Title			
NPI	Phone Number	<u>.</u>			
Send Report Via: Fax Email Portal					
Additional Ordering Provider Name (optional)	Role/Title			
NPI					
Send Report Via: 🛛 Fax 🗋 Email 🗋 Portal					
Fax #/Email:					
SEND ADDITIONAL REPORT COPIES TO (optiona	I)				
Provider Name	GeneDx Acct#				
Fax #/Email:					

ICD-10-CM CODES

ICD-10-CM Codes to support all test(s) ordered

Clinical Diagnosis

Age of Onset

STATEMENT OF MEDICAL NECESSITY

By submission of this test requisition and accompanying sample(s), I: (i) authorize and direct GeneDx to perform the testing indicated; (ii) certify that the person listed as the ordering provider is authorized by law to order the test(s) requested; (iii) certify that any custom panel and/or ordered test(s) requested on this test requisition form are reasonable and medically necessary for the diagnosis and/or treatment of a disease. illness, impairment, symptom, syndrome or disorder; (iv) the test results will determine my patient's medical management and treatment decisions of this patient's condition on this date of service; (v) have obtained this patient's and relatives', when applicable, written informed consent to undergo any genetic testing requested; and (vi) that the full and appropriate diagnosis code(s) are indicated to the highest level of specificity. Date

Signature of Ordering Provider

PAYMENT OPTIONS (Select One)

O INSURANCE BILL	Patient Status				
Select all that apply	O Hospital outpatient O Hospital inp	atient; Date of Discharge:			
Commercial	Not a hospital patient Name of Insurance Carrier	Insurance ID#:			
	Relationship to Insured O Self O Spouse O Child O Other:				
	Policy Holder's Name	Policy Holder's Date of Birth			
	Referral/Prior Authorization # (please attach)	Hold test for cost estimate and contact patient			
	Secondary Insurance Type:	Geommercial insurance only)			
AND BACK COPY OF CARD(S)	Insurance Carrier Insurance ID # Su	ubscriber Name Date of Birth			
	Relationship to Insured O Self O Spouse O Child (Other:			
O PATIENT BILL	If Patient Bill is selected, I am electing patient for this testing. I agree that ne claim to my insurance for this testing send an invoice to the patient listed of	to be treated as a self-pay either GeneDx nor I will submit a I, if I have insurance. GeneDx will above.			
	Authorized Patient/Guardian Signat	ure			
	GeneDx Account #	Disco Sticker/Starse Liere			
	Hospital/Lab Name Place Sticker/Stamp He				

Reflex to FMR1 CGG Repeat Analysis after negative exome

Date of Birth

Reflex to Chromosomal Microarray (MicroarrayDx) after negative exome

Gene

XOMEDX® TESTING OPTIONS						
TEST CODE	TEST NAME	TEST CODE	TEST NAME			
☐ 561a	XomeDx® - Trio*	□ 561a & 561m	 XomeDx® Plus - Trio*, consists of two separate tests[†]: 561a XomeDx® - Trio; and 561m Mitochondrial Genome Sequencing & Deletion Testing 			
☐ 561e	XomeDx® - Duo*	☐ 561e & 561m	 XomeDx* Plus - Duo*, consists of two separate tests[†]: 561e XomeDx* - Duo; and 561m Mitochondrial Genome Sequencing & Deletion Testing 			
☐ 561b	XomeDx® - Proband	□ 561b & 561m	 XomeDx® Plus - Proband, consists of two separate tests[†]: 561b XomeDx® - Proband; and 561m Mitochondiral Genome Sequencing & Deletion Testing 			
* If a Trio or Duo test is ordered, please fill out the Family Member Samples to be Included in Testing section below † XomeDx* Plus components (exome and mito genome) will be billed and reported separately						
XOMEDX® REFLEX TESTING OPTIONS						
TEST CODE	TEST NAME	TEST CODE	TEST NAME			

FAMILY MEMBER SAMPLES TO BE INCLUDED IN TESTING

D 910

FAMILY MEMBER INFORMATION MUST BE PROVIDED BELOW AND SAMPLES MUST BE RECEIVED WITHIN 3 WEEKS FOR INCLUSION IN THE PROBAND'S TEST. Ordered test codes may require adjusting to appropriately correspond with family member samples received. A change in the ordered test will impact billing, including prior benefits investigations. Family members will not receive a separate report.

	First Name	Last Name	DOB	O Asymptomatic O Symptomatic
Biological Mother				O At GeneDx (Accession #:)
	First Name	Last Name	DOB	O Asymptomatic O Symptomatic
Biological Father				O At GeneDx (Accession #:) O Not available O To be sent within 3 weeks
	Relationship to Proband			
Other	First Name	Last Name	DOB	O Asymptomatic O Symptomatic
Relative				O At GeneDx (Accession #:) O Not available O To be sent within 3 weeks

CUSTOM SLICE TESTING OPTIONS						
TEST CODE	TEST NAME	TEST CODE	TEST NAME			
□ TG70	Slice - Single Gene (1 gene) Approved Slice ID:	□ J757	Slice - <i>Xpanded</i> ® (>150 genes, Proband or Trio*) Approved Slice ID:			
Image: Total Silice - Multi-Gene (2-150 genes) Approved Silice ID:						
* If a Trio or Duo	* If a Trio or Duo test is ordered, please fill out the Family Member Samples to be Included in Testing section above					
SKIN DISORDER SLICES						
707	Slice - Epidermolysis Bullosa (EB)	□ 708	Slice - Congenital Ichthyosis			
	REANALYSIS OF XOM	EDX® TESTING	OPTIONS			
These test option before ordering	ns are only appropriate if the patient previously had a XomeDx test (full exor a Reanalysis.	ne analysis) at Ger	neDx. We recommend waiting at least one year from original/prior analysis			
□ 660	0 XomeDx® First Time Reanalysis (no charge) Reason for Reanalysis:					
947	XomeDx® Subsequent Reanalysis (charged)	Is there new clinical information availabile? O Yes O No O Other				
	WRITE-IN TE	ST SELECTIO	N			
Test Code:	Test Name:					

ACMG secondary findings, as discussed in the Informed Consent and Authorization Form, are only returned for the patient if an XomeDx® test (full exome analysis) is completed.

GeneDx tests are frequently updated and improved based upon the most recent scientific evidence. The test codes, genes, and gene quantities listed on this test requisition are subject to change by GeneDx at any time. The most current test menu and list of genes included for a specific test panel may be found on our website, genedx.com. Please note that GeneDx reserves the right to modify and upgrade any ordered panel to the version currently listed on our website.

First Name

□ 522

First Name

Last Name

Date of Birth

Gene

	TI	nis section is	FAMILY HISTORY s not intended for ordering a targeted variant testing report.	
🗆 No Known Family History	□ Pe	edigree Att	ached 🛛 Adopted	
Relationship	Maternal	Paternal	Relevant History	Age at Dx
1	0	0		
2	0	0		
3	0	0		

PREVIOUS GENETIC TESTING* *This section is not intended for ordering a targeted variant testing report.					
Personal or family history o	f genetic te	esting ONo O	Yes (If yes, please complete all field	ds below)	
Relation to patient (self, sibling, etc.), Genetic Test(s) and Result (e.g. positive, negative, etc.). If relative was tested at GeneDx, please also provide their accession #:					
If patient or relative(s) were found to have a positive or VUS result on prior testing, please provide details below. Indicate any Variants of Interest‡ via the checkbox below.					
Relation (self, sibling, etc.)	Gene	Transcript #	c./p. (SNV) or exon # (CNV)	Build, coordinates (CNV)	Variant of Interest [‡] ?
1					
2					
3					
Required for sequence variants: gene, c./p., transcript # Required for CNVs: gene, transcript #, exon # <u>OR</u> build, coordinates					
Abnormal karyotype, FISH, or other results:					
‡ For certain tests, GeneDx may be a	+ For certain tests GeneDx may be able to specifically comment upon the presence or absence of previously identified variant(s) of interest in the report. Complete variant information				

[‡] For certain tests, GeneDx **may** be able to specifically comment upon the presence or absence of previously identified variant(s) of interest in the report. Complete variant information must be provided in the table above at the time the test order is placed. If you do not complete the table above and check off that a previously identified variant is a variant of interest, it will not be possible to comment upon the presence or absence of the variant in the report retrospectively. This service is not applicable to targeted variant testing.

(Continue to the next page)

First Name Last Name Date of Birth CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED) Relevant clinical records are required at the time of sample submission to ensure the information is included in data analysis. Genes of interest: Differential diagnosis: **Pre/Perinatal History Neurological Findings Hearing Impairment** Cystic hygroma Abnormality of nervous system Abnormal newborn screen: 🗆 Ataxia Diaphragmatic hernia Conductive hearing impairment □ Encephalocele Cerebral palsv Sensorineural hearing impairment Growth delay Chorea Increased nuchal translucency Cortical visual impairment **Endocrine Findings** Intrauterine growth retardation 🗆 Dementia Delayed puberty □ Nonimmune hydrops fetalis Dysarthria Diabetes insipidus □ Oligohydramnios Dýskinesia Diabetes mellitus □ Omphalocele Dysphasia □ Hyperthyroidism Polyhydramnios Dystonia □ Hypophosphatemia □ Encephalopathy Prematurity GA: □ Hypothyroidism Prolonged neonatal jaundice □ Headaches Maturity-onset diabetes of the young □ Hemiplegia Rickets □ Infantile spasms **Structural Brain Abnormalies** □ Migraines □ Abnormal myelination □Myoclonus **Respiratory Findings** Abnormality of basal ganglia D Parkinsonism 🗆 Asthma Abnormality of brainstem Peripheral neuropathy □ Bronchiectasis Abnormality of periventricular white matter □ Seizures □ Hyperventilation Abnormality of the corpus callosum Sensory neuropathy □ Hypoventilation Aplasia/hypoplasia of cerebellar vermis □ Spasticity aplasia/hypoplasia of cerebellum □ Syncope □ Pulmonary fibrosis Arnold chiari malformation □ Tremors □ Respiratory insufficiency Cerebellar atrophy □ Vertigo Heterotopia (periventricular nodular heterotopia) Hematologic or Immunologic Findings Craniofacial/Dysmorphism □ Holoprosencephaly □ Allergic rhinitis Hydrocephalus Abnormal facial shape (dysmorphic □ Anemia Leukodystrophy features) specify: □ Immunodeficiency □ Lissencephaly □ Brachycephaly □ Neutropenia □ Pachygyria Cleft lip and/or palate □ Pancytopenia Polymicrogyria Coarse facial features □ Recurrent infections □ Ventriculomegaly Craniosynostosis □ Thrombocytopenia ☐ Macrocephaly □ Microcephaly **Developmental/Behavioral Findings** □ Short neck Skin/Hair Findings □ Absent speech □ Synophrys Abnormal blistering of the skin □ Aggressive behavior Abnormality of nail □ Anxiety □ Alopecia **Eye Defects**/Vision Autistic behavior □ Anhidrosis □ Abnormality of vision Cognitive impairment □ Café-au-lait macules Delayed speech & language development □ Anophthalmia Coarse hair Developmental regression □ Cataracts Cutis laxa Coloboma Dysarthria 🗆 Eczema Gait disturbance Corneal opacity □ Hemangiomas Global developmental delay Ectopia lentis □ Hyperextensible skin □ Hyperactivity External ophthalmoplegia Hyperpigmentation of the skin □ Incoordination □ Microphthalmia □ Hypohidrosis □Myopia □ Intellectual disability Hypopigmentation of the skin Learning disability Nystagmus □ Ichthyosis Memory impairment □ Optic atrophy □ Skin rash □ Sleep disturbance Optic neuropathy

□ Stereotypy

- □ Ptosis □ Retinal detachment 🗆 Retinitis pigmentosa □ Strabismus
- □ Sparse hair □ Telangiectasia Vascular skin abnormality UVelvety skin

Gene

Gene Date of Birth

First Name

Last Name

CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED)

Cardiac Findings

Abnormal heart morphology □ Amyloidosis □ Aortic root dilation □ Arrhvthmia □ Atrial septal defect Bicuspid aortic valve Bradycardia Coarctation of aorta Dilated cardiomyopathy □ Heterotaxy □ Hypertension Hypertrophic cardiomyopathy Mitral valve prolapse □ Noncompaction cardiomyopathy Patent ductus arteriosis Patent foramen ovale Prolonged QTc interval □ Sudden death □ Tetralogy of Fallot Uventricular septal defect Uventricular tachycardia

Gastrointestinal Findings

- □ Constipation
- Diarrhea
- Duodenal stenosis/atresia Exocrine pancreatic insufficiency □ Failure to thrive □ Feeding difficulties Gastroesophageal reflux □ Hepatomegaly Inflammatory bowel disease Intrahepatic biliary atresia Laryngomalacia
- □ Nausea
- Pancreatitis
- Pyloric stenosis
- Tracheoesohageal fistula
- □ Vomiting

Genitourinary Findings

- Ambiguous genitalia Cryptorchidism Cystic renal dysplasia ☐ Horseshoe kidney □ Hydronephrosis □ Hypospadias 🗆 Inguinal hernia ☐ Micropenis □ Nephrolithiasis Polycystic kidney disease □ Renal agenesis
- Umbilical hernia

Musculoskeletal Findings

□ Abnormal connective tissue Abnormal form of the vertebral bodies □ Abnormality of the ribs □ Arachnodactvlv 🗆 Arthralgia □ Arthrogryposis □ Bruising susceptibility □ Clinodactyly Decreased muscle mass □ Ectrodactyly Exercise intolerance □ Fatique □ Hemihypertrophy Hypertonia □ Hypotonia □ Joint hypermobility ☐ Muscle weakness □ Myalgia □ Myopathic facies □ Myopathy □ Osteoarthritis 🗆 Osteopenia □ Pain □ Pectus carinatum □ Pectus excavatum Polydactyly □ Recurrent fractures □ Rhabdomyolysis □ Scoliosis □ Short stature Skeletal dysplasia □ Syndactyly □ Tall stature

Metabolic Findings

(Attached relevant lab reports/values) Abnormal activity of mitochondrial respiratory chain Abnormal newborn screen: Abnormality of mitochondrial metabolism Elevated CPK Elevated hepatic transaminase □ Hyperammonemia □ Hyperglycemia □ Hypoammonemia □ Hypoglycemia □ Increased serum pyruvate □ Lactic acidosis 🗆 Plasma AA: Urine OA:

Vascular System

□ Aneurysm Arterial calcification □ Arterial dissection □ Arterial tortuositv Arteriovenous malformation □ Epistaxis Lymphedema Pulmonary hypertension □ Stroke

Cancer

□Туре:	
Location:	
Age of onset:	
Age of onset:	

Other Testing/Imaging

(Please provide	copy or	report if	possible)
-----------------	---------	-----------	-----------

🗆 Echo:
🗆 EEG:
MRI:
□ Muscle Biopsy:
Ultrasound:
□ X-rays:

Additional Clinical Findings:

INFORMED CONSENT

First Name	Last Name	Date of Birth

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

- 1. <u>Positive</u>: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
- 2. <u>Negative</u>: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
- 3. Variant of Uncertain Significance (VUS): A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
- 4. <u>Unexpected Results</u>: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care.

Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information GeneDx used to interpret my results. Healthcare providers can contact GeneDx at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents.

Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that GeneDx will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.

- 2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
- Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
- 4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
- 5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

INTERNATIONAL SAMPLES

If I reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my residence.

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. GeneDx will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made.

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and GeneDx will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. GeneDx will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this deidentified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. GeneDx shares this type of information with healthcare providers, scientists, and healthcare databases. GeneDx will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. GeneDx believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.

Gene

INFORMED CONSENT

First Name

Last Name

Date of Birth

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

· Applicable only for full exome sequencing and genome sequencing tests

• Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT?

All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES?

The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS

Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified nor reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE

For insurance billing, I understand and authorize GeneDx to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to GeneDx.

I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by GeneDx as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by GeneDx on my behalf, I agree to endorse the insurance check and forward it to GeneDx within 30 days of receipt as payment towards GeneDx's claim for services rendered.

If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by GeneDx. I further understand and agree that, if I fail to make payment for genetic testing, in accordance with the payment policies of GeneDx, my account may be turned over to an external collection agency for non-payment. I agree to pay any associated collection costs, including attorney fees. By my signature on the GeneDx Test Requisition Form or at the bottom of this form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider.

MEDICARE

A completed Advance Beneficiary Notice (ABN) is required for Medicare patients, when applicable. Please visit our website, www.genedx.com/billing for more information.